Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: A cross-sectional study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 37, Issue 1, 2012, Pages 182-187

  Mizuno, Yuya ^a   Bies, Robert R ^b,c,d   Remington, Gary ^b   Mamo, David C ^b,e   Suzuki, Takefumi ^a,f   Pollock, Bruce G ^b,e   Tsuboi, Takashi ^a   Watanabe, Koichiro ^a   Mimura, Masaru ^a   Uchida, Hiroyuki ^a,b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Indiana Clinical and Translational Sciences Institute   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f Department of Psychiatry   (Japan)

Author keywords

Antipsychotic; Dopamine; Maintenance; Olanzapine; Risperidone; Schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR; OLANZAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; ASIAN; CAUCASIAN; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINE RECEPTOR BLOCKING; DRUG BLOOD LEVEL; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; RECEPTOR OCCUPANCY; SCHIZOPHRENIA;

ADULT; AGED; BENZODIAZEPINES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN BINDING; RECEPTORS, DOPAMINE D2; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84862787687     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.12.013     Document Type: Article

References (36)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington, DC. fourth ed.
2. Barnes T.R. A rating scale for drug-induced akathisia. Br J Psychiatry 1989, 154:672-676.
3. Beal B., Sheiner L. NONMEM user's guide, part I 1992, University of California, San Francisco.
4. Bedard A.M., Maheux J., Levesque D., Samaha A.N. Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues. Neuropsychopharmacology 2011, 36(6):1248-1259.
5. Bigos K.L., Bies R.R., Pollock B.G. Population pharmacokinetics in geriatric psychiatry. Am J Geriatr Psychiatry 2006, 14(12):993-1003.
6. Bigos K.L., Pollock B.G., Coley K.C., Miller D.D., Marder S.R., Aravagiri M., et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008, 48(2):157-165.
7. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992, 49(7):538-544.
8. Feng Y., Pollock B.G., Coley K., Marder S., Miller D., Kirshner M., et al. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol 2008, 66(5):629-639.
9. Guy W. ECDEU assessment manual for psychopharmacology 1976, U.S. Dept. of Health, Education, and Welfare, Washington, DC.
10. Jin Y., Pollock B.G., Coley K., Miller D., Marder S.R., Florian J., et al. Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Clin Pharmacol 2010, 50(1):73-80.
11. Kapur S., Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27(7):1081-1090.
12. Kapur S., Zipursky R.B., Remington G., Jones C., DaSilva J., Wilson A.A., et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998, 155(7):921-928.
13. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000, 157(4):514-520.
14. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13(2):261-276.
15. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004, 161(2 Suppl.):1-56.
16. Mamo D., Kapur S., Shammi C.M., Papatheodorou G., Mann S., Therrien F., et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004, 161(5):818-825.
17. Mizrahi R., Rusjan P., Aqid O., Graff A., Mamo D.C., Zipursky R.B., et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry 2007, 164(4):630-637.
18. Nyberg S., Farde L., Halldin C., Dahl M.L., Bertilsson L. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995, 152(2):173-178.
19. Ray W.A., Chung C.P., Murray K.T., Hall K., Stein C.M. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009, 360(3):225-235.
20. Remington G., Seeman P., Shammi C., Mann S., Kapur S. "Extended" antipsychotic dosing: rationale and pilot data. J Clin Psychopharmacol 2005, 25(6):611-613.
21. Remington G., Seeman P., Feingold A., Mann S., Shammi C., Kapur S. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2011, 72(8):1042-1048.
22. Sheiner L.B., Rosenberg B., Marathe W. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977, 5(5):445-479.
23. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970, 212:11-19.
24. Turrone P., Remington G., Kapur S., Nobrega J.N. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol Psychiatry 2005, 57(4):406-411.
25. Uchida H., Suzuki T., Mamo D.C., Mulsant B.H., Tanabe A., Inagaki A., et al. Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan. Am J Geriatr Psychiatry 2008, 16(7):584-593.
26. Uchida H., Mamo D.C., Kapur S., Labelle A., Shammi C., Mannaert E.J., et al. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J Clin Psychiatry 2008, 69(8):1281-1286.
27. Uchida H., Pollock B.G., Bies R.R., Mamo D.C. Predicting age-specific dosing of antipsychotics. Clin Pharmacol Ther 2009, 86(4):360-362.
28. Uchida H., Kapur S., Mulsant B.H., Graff-Guerrero A., Pollock B.G., Mamo D.C. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am J Geriatr Psychiatry 2009, 17(3):255-263.
29. Uchida H., Suzuki T., Takeuchi H., Mamo D.C. Analysis of antipsychotic dose reduction. Am J Psychiatry 2010, 167(8):994.
30. Uchida H, Mamo DC, Pollock BG, Suzuki T, Tsunoda K, Watanabe K, et al. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. Therapeut Drug Monit (in press).
31. Uchida H., Takeuchi H., Graff-Guerrero A., Suzuki T., Watanabe K., Mamo D.C. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol 2011, 31(4):497-502.
32. Uchida H., Suzuki T., Takeuchi H., Arenovich T., Mamo D.C. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr Bull 2011, 37(4):788-799.
33. Uchida H., Takeuchi H., Graff-Guerrero A., Suzuki T., Watanabe K., Mamo D.C. Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol 2011, 31(3):318-325.
34. Uchida H., Bies R.R., Suzuki T., Graff-Guerrero A., Pollock B.G., Mulsant B.H., et al. Predicting dopamine D2 receptor occupancy following antipsychotic dose reduction: a pilot PET study. Eur Arch Clin Neurosci 2011, 261(Suppl. 1):65.
35. Wang C.Y., Xiang Y.T., Cain Z.J., Weng Y.Z., Bo Q.J., Zhao J.P., et al. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. Am J Psychiatry 2010, 167(6):676-685.
36. Wessels A.M., Bies R.R., Pollock B.G., Schneider L.S., Lieberman J.A., Stroup S., et al. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. J Clin Pharmacol 2011, 51(11):1587-1591.